NOVO-B.CO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk Prepares to Announce Next-Generation Weight-Loss Drug Trial Results
Novo Nordisk is reportedly preparing to announce clinical trial results for a next-generation weight-loss drug. The company has not disclosed details about the...
Novo Nordisk targets muscle and bone preservation in obesity drug race
In his first interview with Korean media, new Novo Nordisk CEO Mike Doustdar said the company is shifting its focus from weight-loss efficacy alone to the...
Novo Nordisk's Patent Wall Is Crumbling — Can Its Pipeline Outrun the Generic Tide?
Shares of Novo Nordisk edged up 0.2% to $254.30 on Oct. 10, a muted reaction to a potentially seismic development: the European Patent Office's Board of...
Novo Nordisk Loses Patent, Threatening Ozempic and Wegovy Exclusivity From 2031
The European Patent Office’s (EPO) Board of Appeal revoked Novo Nordisk’s patent EP 3 448 416, which covered its semaglutide products Wegovy and Ozempic. The...
Novo Nordisk Presents Early Data Linking Semaglutide to Longer Life
At the ARDD conference, Novo Nordisk presented early data suggesting its GLP-1 receptor agonists, including semaglutide, may support healthier aging and longer...
Novo Nordisk Reports FDA Delays Denecimig Review Over Plant Remediation
Novo Nordisk said the U.S. Food and Drug Administration (FDA) has extended its review of the Biologics License Application (BLA) for denecimig, a treatment for...
Eli Lilly Pressures Novo Nordisk With 23.3% Weight-Loss Trial Result
Eli Lilly reported promising mid-stage trial results for its obesity drug EloraTZP, which produced up to 23.3% weight loss in patients. The company plans to...
Novo Nordisk Licenses Hengrui’s Weekly Oral Obesity Drug in Up-to-$2.6B Deal
Novo Nordisk has signed an exclusive licensing agreement with Chinese drugmaker Hengrui Pharma for HRS-1596, an experimental once-weekly oral weight-loss drug...
Novo Nordisk signs €1.17B Nanexa deal, targeting monthly obesity injections
Novo Nordisk signed a global licensing agreement with Swedish firm Nanexa for its PharmaShell technology. The deal carries a total potential value of up to...
Novo Nordisk CEO Open to a Direct New York Stock Exchange Listing
Novo Nordisk CEO Mike Doustdar stated the company is open to considering a direct listing on the New York Stock Exchange, which would replace the American...
Novo Nordisk’s CagriSema Beats Eli Lilly in Weight Loss Trial
Novo Nordisk announced positive topline results for its next-generation experimental drug, CagriSema, during its Capital Markets Day. The late-stage REIMAGINE...
🔴 Novo Nordisk is trading 6% down; no confirmed September 21, 2026 announcement explains decline
Novo Nordisk is trading 6.23% down at DKK 264.00, with no confirmed September 21, 2026 company announcement directly explaining the decline. - Investors are...
Novo Nordisk strikes $1.4B Orbis deal, turning injectable treatments into pills
Novo Nordisk signed a $1.4 billion drug discovery and licensing agreement with Orbis Medicines. The partnership focuses on developing oral therapies for...
Novo Nordisk Wins EU Support for Haemophilia Drug, Slashing Bleeding Rates
The European Medicines Agency’s CHMP issued a positive opinion for Novo Nordisk’s haemophilia A treatment, FREHEMGO® (denecimig). This recommendation covers...
Novo Nordisk taps Anthropic AI to fast-track drug discovery
Novo Nordisk has partnered with AI firm Anthropic to accelerate the discovery and development of new medicines. The collaboration utilizes Anthropic’s Claude...
Novo Nordisk rebrands to Novo, aiming to reclaim obesity market lead
Danish pharmaceutical giant Novo Nordisk shortened its everyday name to Novo. The rebranding includes the new slogan Lasting Health Starts Now, an updated...
Novo Nordisk Slumps as Morgan Stanley Warns of Ozempic Patent Cliff
Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight. The bank cited a subdued mid-term growth outlook and risks from a looming patent cliff...
Novo Nordisk wins China approval for Wegovy, first GLP-1 for liver disease
Novo Nordisk announced Thursday that China’s National Medical Products Administration approved Wegovy for a new medical use. The drug will treat metabolic...
Novo Nordisk Wegovy Cuts Obesity in 40% of Children, Trial Finds
Novo Nordisk reported positive results from its late-stage STEP Young trial for semaglutide in children aged 6 to under 12. Semaglutide serves as the active...
Novo Nordisk Scraps Two Heart Trials, Stalling Expansion Beyond Obesity Drugs
Novo Nordisk has terminated the HERMES and ATHENA late-stage clinical trials for its experimental drug, ziltivekimab. An independent data monitoring committee...